The drugmaker reached agreements in principle to resolve “substantially all” of the personal injury cases, consumer fraud cases and state attorneys general claims involving its two Cox-2 inhibitor painkillers. Bextra was withdrawn three years ago, while Celebrex remains available. Here’s the breakdown: $745 million applicable to personal injury claims, $60 million for state attorneys general settlements and $89 million to resolve consumer fraud class action claims. Total: $894 million. Pfizer maintains the deals will tackle more than 90 percent of the known personal injury claims alleging the painkillers caused a heart attack, stroke or other injury. The settlement also covers third-party payor class action consumer fraud cases in which plaintiffs alleged economic loss related to the promotion of the meds.
Read article at pharmalot.com
No comments:
Post a Comment